AVEO Pharmaceuticals Inc

+0.05 (+0.92%)
Products, Earnings Announcements

Aveo Oncology Reports Q3 2021 Financial Results

Published: 11/08/2021 21:38 GMT
AVEO Pharmaceuticals Inc (AVEO) - Aveo Oncology Reports Third Quarter 2021 Financial Results and Provides Business Update.
Q3 Loss per Share $0.30.
Q3 Revenue $15.2 Million Versus $3.6 Million.
Aveo Oncology - in 2021, Expects Commercial Spend Will Be About $40 Million, Research and Development Expense Will Be About $30 Million.
Q3 Earnings per Share View $-0.36, Revenue View $13.8 Million -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $22.95 Million
Adjusted EPS is expected to be -$0.17

Next Quarter Revenue Guidance is expected to be $22.77 Million
Next Quarter EPS Guidance is expected to be -$0.17

More details on our Analysts Page.